Division of Health Policy and Management, University of Minnesota, Minneapolis, Minnesota.
Division of Pediatric Epidemiology and Clinical Research, University of Minnesota, Minneapolis, Minnesota.
Pediatr Blood Cancer. 2021 Jan;68(1):e28738. doi: 10.1002/pbc.28738. Epub 2020 Sep 24.
Despite improvements in overall survival for pediatric cancers, treatment disparities remain for racial/ethnic minorities compared to non-Hispanic Whites; however, the impact of race on treatment outcomes for pediatric brain and central nervous system (CNS) tumors in the United States is not well known.
We included 8713 children aged 0-19 years with newly diagnosed primary brain and CNS tumors between 2000 and 2015 from the Census Tract-level SES and Rurality Database developed by Surveillance, Epidemiology, and End Results (SEER) Program. We used chi-square tests to assess differences in sociodemographic, cancer, and treatment characteristics by race/ethnicity and Kaplan-Meier curves and Cox proportional hazards models to examine differences in 10-year survival, adjusting for these characteristics.
Among 8713 patients, 56.75% were non-Hispanic White, 9.59% non-Hispanic Black, 25.46% Hispanic, and 8.19% from "other" racial/ethnic groups. Median unadjusted survival for all pediatric brain tumors was 53 months, but varied significantly by race/ethnicity with a median survival of 62 months for non-Hispanic Whites, 41 months for non-Hispanic Blacks, and 40 months for Hispanic and other. Multivariable analyses demonstrated minority racial groups still had significantly higher hazard of death than non-Hispanic Whites; Hispanic (adjusted hazard ratio [aHR] 1.25 [1.18-1.31]); non-Hispanic Black (aHR 1.12 [1.04-1.21]); other (aHR 1.22 [1.12-1.32]). Results were consistent when stratified by tumor histology.
We identified disparities in survival among racial/ethnic minorities with pediatric brain and CNS tumors, with Hispanic patients having the highest risk of mortality. Eliminating these disparities requires commitment toward promoting heath equity and personalized cancer treatment.
尽管儿科癌症的总体生存率有所提高,但与非西班牙裔白人相比,少数族裔仍存在治疗差异;然而,种族对美国儿科脑和中枢神经系统(CNS)肿瘤治疗结果的影响尚不清楚。
我们纳入了 2000 年至 2015 年间,来自 Surveillance、Epidemiology、and End Results(SEER)计划开发的 Census Tract-level SES 和 Rurality Database 中,8713 名 0-19 岁的初诊原发性脑和 CNS 肿瘤患儿。我们使用卡方检验评估种族/民族之间社会人口统计学、癌症和治疗特征的差异,并使用 Kaplan-Meier 曲线和 Cox 比例风险模型检验 10 年生存率的差异,同时调整这些特征。
在 8713 名患者中,56.75%为非西班牙裔白人,9.59%为非西班牙裔黑人,25.46%为西班牙裔,8.19%来自其他种族/民族群体。所有儿科脑肿瘤未经调整的中位生存时间为 53 个月,但差异显著,非西班牙裔白人为 62 个月,非西班牙裔黑人为 41 个月,西班牙裔和其他种族为 40 个月。多变量分析表明,少数族裔群体的死亡风险仍然明显高于非西班牙裔白人;西班牙裔(调整后的危险比[aHR]1.25[1.18-1.31]);非西班牙裔黑人(aHR 1.12[1.04-1.21]);其他(aHR 1.22[1.12-1.32])。当按肿瘤组织学分层时,结果一致。
我们发现儿科脑和 CNS 肿瘤患者的种族/民族之间存在生存差异,其中西班牙裔患者的死亡率风险最高。消除这些差异需要致力于促进健康公平和个性化癌症治疗。